share_log

又一家生物科技股,早盘一度涨逾48%

Another biotech stock that once rose more than 48% in early trading

富途资讯 ·  Mar 19, 2018 23:13

201803003045496b9b75c58f6.png

According to Futu News, Hero Therapeutics jumped short and opened high today, rising more than 48% in early trading. The concussion then fell, and the increase narrowed as of press time.

logo

Source: Futu Securities

On the news, the company released the results of an active trial of an advanced stage (Phase 3) anesthetic, mainly for patients undergoing bursitis resection and herniorrhaphy.

The company says reagent HTX-011 has achieved positive results in phase III of the clinical trial, reaching all major and critical secondary endpoints. Within 72 hours after operation, pain intensity and dependence on opiates decreased significantly.

"HTX-011 is the first and only long-acting local anesthetic that significantly reduces pain and dependence on opiates in the 72 hours after phase III surgery compared to the use of bupivacaine (bupivacaine), the standard-of-care local anesthetic currently used to control postoperative pain," the company said in a statement. "

The company CEO Barry Quart said it would submit a new drug application to FDA in the second half of the year."if the application is approved, we believe that by reducing the postoperative use of opiates, it will greatly alleviate the crisis of opioid overuse and at the same time relieve the pain of patients. "

A single dose of HTX-011 can relieve postoperative pain and inflammation at the surgical wound, directly covering the affected tissue through a needle-free syringe, so it is easier, faster and safer than the current large number of local anesthetics that need to be injected.

Heron Therapeutics is a commercial biotechnology company dedicated to improving patients' lives and developing the best treatments to address some of the most important but unmet needs of patients today.

Heron is developing innovative drugs for cancer treatment and pain relief by applying innovative technology to approved APIs.

Heron has risen more than 40 per cent this year, compared with less than 2 per cent for the S & P 500 over the same period. (Wen / Wu Dongxia / tr. by Phil Newell)

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment